Adrian H Heald1,2, Mark Livingston3, Zuzanna Bien4, Gabriela Y C Moreno5, Ian Laing1, Mike Stedman6. 1. The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. 2. Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford, England. 3. Department of Blood Sciences, Walsall Manor Hospital, Walsall, UK. 4. St. Peters College, Oxford, UK. 5. Head of Medical Department, High Specialty Regional Hospital, Ixtapaluca, Mexico City, Mexico. 6. RES Consortium, Andover, Wiltshire, UK.
Abstract
BACKGROUND: In the financial year 2016/17 there were 52.0 million items prescribed for diabetes at a total net ingredient cost of £983.7 million - up from 28.9 million prescription items and £572.4 million in 2006/07. Anti-diabetes drugs (British National Formulary section 6.1.2) make up 45.1 per cent of the total £983.7 million net ingredient cost of drugs used in diabetes and account for 72.0 per cent of prescription items for all diabetes prescribing. METHODS: We examined the way that agents licensed to treat type 2 diabetes were used across GP practices in England in the year 2016/2017. Analysis was at a GP practice level not at the level of patient data. RESULTS: Annual prescribing costs / patient / medication type for monotherapy varied considerable from £11/year for gliclazide and glimepiride to £885/year for Liraglutide. The use of SGLT-2i agents grew strongly at 70% per annum to around 100,000 DDD with prescriptions seen in 95% of GP practices. Liraglutide expenditure (11% of total) was high for a relatively small number of patients (1.3% of Defined Daily Doses), with still significant spend on exenatide. Liraglutide use significantly exceeded that of other glucagon-like peptide-1 (GLP-1) agonists. CONCLUSIONS: Our work demonstrates the significant cost of medication to modulate tissue glucose levels in type 2 diabetes and the dominance of some non-generic preparations in terms of number of prescriptions and overall spend. There are some older sulphonylureas in use, which should not generally be prescribed. Regular audit of patient treatment at a general practice level will ensure appropriate targeted use of licensed medications and of their cost effectiveness.
BACKGROUND: In the financial year 2016/17 there were 52.0 million items prescribed for diabetes at a total net ingredient cost of £983.7 million - up from 28.9 million prescription items and £572.4 million in 2006/07. Anti-diabetes drugs (British National Formulary section 6.1.2) make up 45.1 per cent of the total £983.7 million net ingredient cost of drugs used in diabetes and account for 72.0 per cent of prescription items for all diabetes prescribing. METHODS: We examined the way that agents licensed to treat type 2 diabetes were used across GP practices in England in the year 2016/2017. Analysis was at a GP practice level not at the level of patient data. RESULTS: Annual prescribing costs / patient / medication type for monotherapy varied considerable from £11/year for gliclazide and glimepiride to £885/year for Liraglutide. The use of SGLT-2i agents grew strongly at 70% per annum to around 100,000 DDD with prescriptions seen in 95% of GP practices. Liraglutide expenditure (11% of total) was high for a relatively small number of patients (1.3% of Defined Daily Doses), with still significant spend on exenatide. Liraglutide use significantly exceeded that of other glucagon-like peptide-1 (GLP-1) agonists. CONCLUSIONS: Our work demonstrates the significant cost of medication to modulate tissue glucose levels in type 2 diabetes and the dominance of some non-generic preparations in terms of number of prescriptions and overall spend. There are some older sulphonylureas in use, which should not generally be prescribed. Regular audit of patient treatment at a general practice level will ensure appropriate targeted use of licensed medications and of their cost effectiveness.
Authors: Viswanathan Mohan; Kamlesh Khunti; Siew P Chan; Fadlo F Filho; Nam Q Tran; Kaushik Ramaiya; Shashank Joshi; Ambrish Mithal; Maïmouna N Mbaye; Nemencio A Nicodemus; Tint S Latt; Linong Ji; Ibrahim N Elebrashy; Jean C Mbanya Journal: Diabetes Ther Date: 2019-11-26 Impact factor: 2.945
Authors: Adrian Heald; Mark Davies; Mike Stedman; Mark Livingston; Mark Lunt; Anthony Fryer; Roger Gadsby Journal: BMJ Open Date: 2019-09-06 Impact factor: 2.692
Authors: Kristian L Funck; Jakob S Knudsen; Troels K Hansen; Reimar W Thomsen; Erik L Grove Journal: Diabetes Obes Metab Date: 2020-11-17 Impact factor: 6.577